|Coating with a drug candidate (blue) inhibits interaction between amyloid beta and other proteins, like the antioxidant enzyme catalase. Illustration by Christopher Burke.|
A new study at the University of California, San Diego, shows that amyloid beta disrupts one of the brain’s anti-oxidant proteins and demonstrates a way to protect that protein, and perhaps others, from amyloid’s harmful effects.
“Amyloid seems to cause damage to cells,” said chemistry professor Jerry Yang. “We have reported in a very detailed way one potential interaction of how amyloid can cause disease, and we found a way to stop it.” His group’s report of their results will appear in the Journal of Biological Chemistry in December.
Their study focused on catalase, an enzyme that mops up excess oxidants, because catalase normally helps to prevent the kind of damage seen in the brains of patients with Alzheimer’s disease and previous work had found catalase proteins deposited within amyloid plaques.
Lila Habib, a bioengineering graduate student and the first author of the report, added amyloid to cultured neural cells and looked at its effects.
“We were able to determine that amyloid beta and this anti-oxidant enzyme, catalase, interact, and that this interaction harmed catalase so it wasn’t able to perform its physiological function: to degrade hydrogen peroxide into oxygen and water,” she said.
When Habib coated the amyloid with a small molecule designed to prevent its interaction with other proteins, she was able to restore the activity of catalase and return hydrogen peroxide to normal levels within the cells.
The coating Habib used to probe the interaction between amyloid and catalase is a candidate drug – one of a class of molecules that Yang’s lab has developed.
“Not only are we learning more about the disease, but we are also developing a potential strategy for treatment,” said Yang, who is currently testing the new approach in a mouse model of the disease.
Media Contact: Susan Brown email@example.com or (858)246-0161